Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for GSK plc (GSK) provides access to the company’s regulatory disclosures as a foreign private issuer. GSK files an annual report on Form 20-F and frequent current reports on Form 6-K under the Securities Exchange Act of 1934. These documents, together with information on American Depositary Shares listed on the New York Stock Exchange, form a key source of official information for investors analyzing GSK stock.
Recent Form 6-K filings include multiple transaction notifications for persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. These reports detail acquisitions of ordinary shares or American Depositary Shares, often through dividend reinvestment plans, share reward plans or the exercise of options under GSK’s share save arrangements, and specify trade dates, prices, volumes and trading venues such as the London Stock Exchange and New York Stock Exchange.
Other 6-K filings report total voting rights, including the number of issued ordinary shares, treasury shares and the resulting total voting rights figure. This information helps shareholders determine whether they must notify changes in their holdings under applicable disclosure rules. Additional 6-K submissions incorporate press releases on significant product approvals, clinical trial results and agreements, such as approvals for Exdensur (depemokimab), Nucala (mepolizumab) in COPD, Shingrix prefilled syringe presentations, and positive phase III results for bepirovirsen in chronic hepatitis B.
On Stock Titan, these filings are complemented by AI-powered summaries that explain the practical meaning of each document. Investors can quickly understand insider dealing reports, changes in capital structure, and major regulatory or clinical events without reading every line of the original filing. Real-time updates from EDGAR ensure that new GSK 6-K submissions, as well as the annual 20-F, appear promptly, while insider transactions analogous to Form 4 in the US domestic context are captured through the PDMR transaction notifications.
By using this page, users can review GSK’s historical and current SEC filings, track patterns in executive and director share dealings, and connect clinical and regulatory announcements to their formal disclosure record, all with the support of AI-generated explanations.
GSK announces a significant regulatory milestone as Japan's Ministry of Health, Labour and Welfare (MHLW) accepts their application to expand the use of Arexvy, their RSV vaccine, to adults aged 18-49 at increased risk of severe RSV disease.
Key developments:
- If approved, Arexvy would be the first RSV vaccine in Japan for this age group
- Application supported by positive Phase IIIb trial (NCT06389487) data showing non-inferior immune response in at-risk adults aged 18-49 compared to those 60+
- Currently approved in Japan for adults 60+ and at-risk adults 50+
- Trial involved 1,458 participants across 52 locations in 6 countries
RSV affects an estimated 64 million people globally annually and can lead to severe complications, particularly in at-risk populations. GSK is pursuing similar regulatory expansions in the US and Europe, positioning Arexvy as a leading preventive solution for RSV disease across multiple age groups.
GSK plc submitted a Form 6-K detailing routine activity under its existing share-buyback programme. Acting through Merrill Lynch International, the company repurchased 473,254 ordinary shares on 19 June 2025 at prices ranging from 1,424.00p to 1,441.50p, producing a volume-weighted average price of 1,434.72p.
Since the mandate began on 4 June 2025, 4,664,836 shares have been acquired. The latest transaction lifts treasury holdings to 222,799,219 shares, equivalent to 5.44 % of total voting rights. Shares outstanding (excluding treasury) now stand at 4,092,502,370, which is also the updated denominator for disclosure threshold calculations under the FCA’s Disclosure Guidance & Transparency Rules.
The filing includes a granular trade log for London Stock Exchange executions; no purchases occurred on CBOE venues. All shares will be held in treasury and may be used for future capital management purposes such as employee share plans or cancellation.
GSK plc filed a Form 6-K detailing daily activity under its ongoing share repurchase programme. On 18 June 2025, the company bought 468,255 ordinary shares (31 ⅔ p nominal value) through its broker Merrill Lynch International. Purchase prices ranged from 1,444.00 p to 1,469.50 p with a volume-weighted average of 1,454.83 p per share.
The transaction forms part of the non-discretionary buyback mandate announced on 4 June 2025. Cumulatively since that date, 4,191,582 shares have been repurchased.
Following the latest purchase, GSK holds 222,325,965 shares in treasury, representing 5.43 % of voting rights. Shares outstanding excluding treasury now total 4,092,975,624; this figure is the denominator shareholders should use for FCA DTR notifications.
No financial performance metrics or strategic changes were disclosed; the filing is limited to share buyback execution details.